- Email: [email protected]
Seminars in oncology current perspectives in the treatment of small cell lung cancer
SEMINARS Current
Perspectives
in the Treatment
Unlabeled Uses or Investigational
F
OR
ADDITIONAL
proved
consult
uses, the
information check
the
IN ONCOLOGY
package
of Commercial Uses Not Yet
about
ap-
labeling
or
Physician’s Desk Reference.
Combined-Modality Therapy of Limited-Stage Small Cell Lung Cancer, Walter J. Curran, Jr Topotecan is indicated for treatment of small cell lung cancer (SCLC)-sensitive disease after failure of first-line chemotherapy. Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Etoposide is approved in combination with other approved chemother, apeutic agents as first-line treatment in patients with SCLC. Cyclophosphamide, vincristine, cisplatin, lomustine, methotrexate, paclitaxel, vinorelbine, irinotecan, gemcitabine, and docetaxel are not approved alone or in combination for treatment of SCLC. Concurrent Versus Sequential Radiotherapy for Small Cell Lung Cancer, Tsukada et al Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Etoposide is approved in combination with other approved chemotherapeutic agents as firstline treatment in patients with SCLC. Cisplatin, cyclophosphamide, and vincristine are not approved alone or in combination for treatment of SCLC. New Drugs in Extensive-Disease
Chemotherapy-Naive Small Cell Lung
Patients With Cancer, David S.
Ettinger Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Paclitaxel, docetaxel, irinotecan, vinorelbine, and gemcitabine are not approved alone or in combination for treatment of SCLC. Alternatives to Chemotherapy and Radiotherapy in the Treatment of Small Cell Lung Cancer, Frances A. Shepherd Doxorubicin has been successfully utilized to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Etoposide is approved in combination with other approved chemotherapeutic agents as first-line treatment in patients with SCLC. Cisplatin, carbopla-
Seminon
in Oncology, Vol 28, No 2. Suppl 4 (April),
200 I: p 6 I
of Small
Cell
Lung
Cancer
Products Approved
tin, vincristine, vinorelbine, gemcitabine, methotrexate, cyclophosphamide, lomustine, mitomycin, and tamoxifen are not approved alone or in combination for treatment of SCLC. Interferon alpha 2 is not approved alone or in combination for treatment of SCLC. Warfarin, heparin, and aspirin have not been approved for use for treatment of SCLC. Argenine vasopressin is not approved alone or in combination for treatment of SCLC. The Importance of Drug Diversity in the Treatment of Small Cell Lung Cancer, Neoin Murray Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Etoposide is approved in combination with other approved chemotherapeutic agents as firstline treatment in patients with SCLC. Cyclophosphamide, vincristine, cisplatin, lomustine, methotrexate, ifosfamide, and paclitaxel are not approved alone or in combination for treatment of SCLC. Paclitaxel-Based Three-Drug Combinations for the Treatment of Small Cell Lung Cancer: A Review of the Sarah Cannon Cancer Center Experience, Hainsworth, Burris, and Greco Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Etoposide is approved in combination with other approved chemotherapeutic agents as first-line treatment in patients with SCLC. Paclitaxel, docetaxel, gemcitabine, irinotecan, and carboplatin are not approved alone or in combination for treatment of SCLC. The combinations of paclitaxel/carboplatin/etoposide and paclitaxel/carbo, platin/topotecan have not been approved for use in the treatment of SCLC. Treatment of Relapsed Small Cell Lung Cancer, Postmus and Smit Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Etoposide is approved in combination with other approved chemotherapeutic agents as first-line treatment in patients with SCLC. Cyclophosphamide, vincristine, methotrexate, cisplatin, carboplatin, ifosfamide, cytarabine, vinorelbine, docetaxel, teniposide, irinotecan, and paclitaxel are not approved alone or in combination for treatment of SCLC.
61
Perspectives
in the Treatment
Unlabeled Uses or Investigational
F
OR
ADDITIONAL
proved
consult
uses, the
information check
the
IN ONCOLOGY
package
of Commercial Uses Not Yet
about
ap-
labeling
or
Physician’s Desk Reference.
Combined-Modality Therapy of Limited-Stage Small Cell Lung Cancer, Walter J. Curran, Jr Topotecan is indicated for treatment of small cell lung cancer (SCLC)-sensitive disease after failure of first-line chemotherapy. Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Etoposide is approved in combination with other approved chemother, apeutic agents as first-line treatment in patients with SCLC. Cyclophosphamide, vincristine, cisplatin, lomustine, methotrexate, paclitaxel, vinorelbine, irinotecan, gemcitabine, and docetaxel are not approved alone or in combination for treatment of SCLC. Concurrent Versus Sequential Radiotherapy for Small Cell Lung Cancer, Tsukada et al Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Etoposide is approved in combination with other approved chemotherapeutic agents as firstline treatment in patients with SCLC. Cisplatin, cyclophosphamide, and vincristine are not approved alone or in combination for treatment of SCLC. New Drugs in Extensive-Disease
Chemotherapy-Naive Small Cell Lung
Patients With Cancer, David S.
Ettinger Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Paclitaxel, docetaxel, irinotecan, vinorelbine, and gemcitabine are not approved alone or in combination for treatment of SCLC. Alternatives to Chemotherapy and Radiotherapy in the Treatment of Small Cell Lung Cancer, Frances A. Shepherd Doxorubicin has been successfully utilized to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Etoposide is approved in combination with other approved chemotherapeutic agents as first-line treatment in patients with SCLC. Cisplatin, carbopla-
Seminon
in Oncology, Vol 28, No 2. Suppl 4 (April),
200 I: p 6 I
of Small
Cell
Lung
Cancer
Products Approved
tin, vincristine, vinorelbine, gemcitabine, methotrexate, cyclophosphamide, lomustine, mitomycin, and tamoxifen are not approved alone or in combination for treatment of SCLC. Interferon alpha 2 is not approved alone or in combination for treatment of SCLC. Warfarin, heparin, and aspirin have not been approved for use for treatment of SCLC. Argenine vasopressin is not approved alone or in combination for treatment of SCLC. The Importance of Drug Diversity in the Treatment of Small Cell Lung Cancer, Neoin Murray Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Etoposide is approved in combination with other approved chemotherapeutic agents as firstline treatment in patients with SCLC. Cyclophosphamide, vincristine, cisplatin, lomustine, methotrexate, ifosfamide, and paclitaxel are not approved alone or in combination for treatment of SCLC. Paclitaxel-Based Three-Drug Combinations for the Treatment of Small Cell Lung Cancer: A Review of the Sarah Cannon Cancer Center Experience, Hainsworth, Burris, and Greco Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Etoposide is approved in combination with other approved chemotherapeutic agents as first-line treatment in patients with SCLC. Paclitaxel, docetaxel, gemcitabine, irinotecan, and carboplatin are not approved alone or in combination for treatment of SCLC. The combinations of paclitaxel/carboplatin/etoposide and paclitaxel/carbo, platin/topotecan have not been approved for use in the treatment of SCLC. Treatment of Relapsed Small Cell Lung Cancer, Postmus and Smit Doxorubicin has been successfully used to produce regression in disseminated neoplastic conditions such as bronchogenic carcinoma of the small cell histologic type. It is not approved in combination with other agents in SCLC. Topotecan is indicated for treatment of SCLC-sensitive disease after failure of first-line chemotherapy. Etoposide is approved in combination with other approved chemotherapeutic agents as first-line treatment in patients with SCLC. Cyclophosphamide, vincristine, methotrexate, cisplatin, carboplatin, ifosfamide, cytarabine, vinorelbine, docetaxel, teniposide, irinotecan, and paclitaxel are not approved alone or in combination for treatment of SCLC.
61